Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Orionis Biosciences Inc. oversees a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There are 3 pending office actions currently active within this portfolio. These actions are distributed across 3 distinct art units. The prosecution involves 3 distinct examiners.
CHATTIN, AMY MARIE is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Since there are 3 distinct examiners for 3 pending office actions, each examiner is responsible for a single case. This distribution indicates that no single examiner has a dominant influence over the current prosecution workload. Each matter is being evaluated by a different individual at the USPTO.
Managing 3 pending office actions across 3 distinct art units requires a range of technical expertise. The applicant must also adapt to the different procedural styles of 3 distinct examiners. While CHATTIN, AMY MARIE handles 1 pending action, the overall strategy must be diversified to address the unique challenges presented by all 3 distinct examiners and their respective units for Orionis Biosciences Inc.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHATTIN, AMY MARIE | 1 | 72.2% | +45.7% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286147 | IL-2 BASED CONSTRUCTS | CHATTIN, AMY MARIE | — |
| 17785359 | DETECTION OF MOLECULAR INTERACTIONS | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17763344 | PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 3d overdue |
| 18286147 | IL-2 BASED CONSTRUCTS | CHATTIN, AMY MARIE | — |
| 17785359 | DETECTION OF MOLECULAR INTERACTIONS | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1637 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286147 | IL-2 BASED CONSTRUCTS | CHATTIN, AMY MARIE | 1643 | §102§103§112 | Non-Final OA | — | Pending | Oct 09, 2023 |
| 17785359 | DETECTION OF MOLECULAR INTERACTIONS | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103 | Non-Final OA | — | Pending | Jun 14, 2022 |
| 17763344 | PD-L1 TARGETED CHIMERIC PROTEINS AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | §112DP | Non-Final OA | 3d overdue | Pending | Mar 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrionis Biosciences Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Amy Marie Chattin has the most, with 1 of Orionis Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
